Related articles
-
NewsShiitake-derived β-glucan inhibits human cervical cancer progression through DMBT1
A team of researchers investigated the molecular mechanism underlying the anti-cervical cancer activity of Lentinus edodes-derived β-glucan (LNT) and, for the first time, identified DMBT1 as a key target.
-
NewsNew strategy to break resistance-yield trade-off in rice by pathogen-inducible gene expression
A research team has developed a genetic strategy to enhance broad-spectrum disease resistance in rice without compromising plant growth and yield, a major challenge in crop breeding.
-
NewsHigh‑fat diets linked to rapid decline in protective gut immune cells
In a preclinical study, researchers found that even short-term exposure to high levels of dietary fat results in a quick and selective loss of critical gut immune cells called ILC3s, promoting intestinal permeability and inflammation.
More from News
-
NewsCharacteristics of CD4+T-cell reduction and pulmonary infections in critically ill immunocompromised patients
A new study investigates the relationship between reduced CD4+T-cell counts and lung infections in immunosuppressed patients admitted to intensive care units (ICUs).
-
NewsNitrogen addition reshapes forest microbes: A five-year insight into community dynamics
A new study reveals how long-term nitrogen enrichment influences soil bacterial communities and network stability, with surprising insights into ecological processes and dissolved organic matter’s critical role.
-
NewsVanderbilt Center for Antibody Therapeutics signs agreement to develop anti-measles antibody treatment
The Vanderbilt Center for Antibody Therapeutics has signed an option agreement with Saravir Biopharma Inc. for the company to develop human monoclonal antibodies isolated in the laboratory of James Crowe Jr., MD, for the treatment and prevention of measles.
No comments yet